Apostle Revenue and Competitors
Estimated Revenue & Valuation
- Apostle's estimated annual revenue is currently $3.6M per year.
- Apostle's estimated revenue per employee is $155,000
Employee Data
- Apostle has 23 Employees.
- Apostle grew their employee count by 5% last year.
Apostle's People
Name | Title | Email/Phone |
---|---|---|
1 | VP Bioinformatics & Co-founder | Reveal Email/Phone |
2 | Co-founder & SVP | Reveal Email/Phone |
3 | VP, Chemistry | Reveal Email/Phone |
4 | VP Business Operations | Reveal Email/Phone |
5 | Business Coordinator | Reveal Email/Phone |
6 | Scientist | Reveal Email/Phone |
Apostle Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Apostle?
Apostle Inc. is a biotechnology company focusing on cell-free DNA technologies used in a liquid biopsy - a developing technology that can have clinical applications in early cancer detection, cancer monitoring, non-invasive prenatal tests and many other potentials. • BioSpace Top 20 Life Science Startups to Watch (2018) • A Stanford University StartX company (2018) • Featured in: Cell-Free DNA Isolation Kit. Science. 17 May 2019:Vol. 364, Issue 6441, pp. 696. DOI: 10.1126/science.364.6441.696-a. (New Products section)
keywords:N/AN/A
Total Funding
23
Number of Employees
$3.6M
Revenue (est)
5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $3.1M | 23 | 0% | $41M |
#2 | $2.3M | 23 | -32% | $30.5M |
#3 | $3.3M | 23 | N/A | N/A |
#4 | $1.8M | 23 | 21% | $73.3M |
#5 | $1.6M | 23 | 5% | N/A |